Zymeworks stock falls 3.12 percent after Theravance deal announced. Continued

Published on 10/04/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zymeworks raised 2026 revenue guidance to USD 278 million-292 million on September 28, 2026. Its Nasdaq shares stood at USD 25.15 after the October 2 close.

ZYME, US98985Y1082, Illustration mit AI erstellt.

Zymeworks (ISIN US98985Y1082) stock closed at USD 25.15 on Nasdaq on October 2, 2026, down 3.12 percent from the prior close. On September 28, 2026, Zymeworks raised its 2026 revenue outlook after completing the Theravance Biopharma acquisition.

Theravance adds commercial cash flow

The transaction adds YUPELRI, commercial operations, royalty economics and an R&D portfolio to Zymeworks' asset and royalty strategy. The company expects total 2026 revenue of USD 278 million-292 million and adjusted EBITDA of USD 114 million-128 million, excluding future transactions, according to Zymeworks.

The updated outlook marks a major shift from the latest standalone quarter. In Q2 2026, revenue was USD 4.6 million, down 90.6 percent from USD 48.7 million in the prior-year quarter, while the net loss reached USD 45.0 million, StockTitan reported.

Analysts see higher value

The analyst consensus is Strong Buy across 14 analysts, with an average price target of USD 41.07. That target lies 63.30 percent above the USD 25.15 reference price, according to StockAnalysis.

Yahoo Finance shows an analyst target range of USD 32.00 to USD 60.00 and reports that Citigroup maintained a Buy rating while raising its target from USD 38 to USD 39 on September 29, 2026. The gap between the current quote and the consensus target makes execution of the new commercial strategy the central valuation test.

Zymeworks stock stays below its yearly high

Zymeworks stock closed 19.8 percent below its 52-week high of USD 31.34, while the 52-week low stands at USD 16.00. The market capitalization was USD 1.8 billion and volume was 844,443 shares on October 2, 2026.